These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19030986)

  • 1. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.
    Mauriac L; Romieu G; Bines J
    Breast Cancer Res Treat; 2009 Sep; 117(1):69-75. PubMed ID: 19030986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
    Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
    J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
    Campos SM; Guastalla JP; Subar M; Abreu P; Winer EP; Cameron DA
    Clin Breast Cancer; 2009 Feb; 9(1):39-44. PubMed ID: 19299239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
    McCartney A; Biagioni C; Schiavon G; Bergqvist M; Mattsson K; Migliaccio I; Benelli M; Romagnoli D; Bonechi M; Boccalini G; Pestrin M; Galardi F; De Luca F; Biganzoli L; Piccart M; Gradishar WJ; Chia S; Di Leo A; Malorni L
    Eur J Cancer; 2019 Jun; 114():55-66. PubMed ID: 31059974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
    Chia S; Gradishar W
    Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
    Mauriac L; Pippen JE; Quaresma Albano J; Gertler SZ; Osborne CK
    Eur J Cancer; 2003 Jun; 39(9):1228-33. PubMed ID: 12763210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
    Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
    McCormack P; Sapunar F
    Clin Breast Cancer; 2008 Aug; 8(4):347-51. PubMed ID: 18757262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
    J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer.
    Chin YS; Beresford MJ; Ravichandran D; Makris A
    Breast; 2007 Aug; 16(4):436-9. PubMed ID: 17418575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
    Zaman K; Winterhalder R; Mamot C; Hasler-Strub U; Rochlitz C; Mueller A; Berset C; Wiliders H; Perey L; Rudolf CB; Hawle H; Rondeau S; Neven P
    Eur J Cancer; 2015 Jul; 51(10):1212-20. PubMed ID: 25892646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
    Falandry C; Debled M; Bachelot T; Delozier T; Crétin J; Romestaing P; Mille D; You B; Mauriac L; Pujade-Lauraine E; Freyer G
    Breast Cancer Res Treat; 2009 Aug; 116(3):501-8. PubMed ID: 19020973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
    Abram P; Maass N; Rea D; Simon SD; Steger GG
    Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Turner NC; Swift C; Kilburn L; Fribbens C; Beaney M; Garcia-Murillas I; Budzar AU; Robertson JFR; Gradishar W; Piccart M; Schiavon G; Bliss JM; Dowsett M; Johnston SRD; Chia SK
    Clin Cancer Res; 2020 Oct; 26(19):5172-5177. PubMed ID: 32546646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of the use of Exemestane in patients with metastatic breast cancer.
    Takashima S; Kiyoto S; Takahashi M; Hara F; Takabatake D; Aogi K; Ohsumi S
    Breast Cancer; 2011 Jul; 18(3):189-94. PubMed ID: 21437667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
    Howell A; Robertson JF; Vergote I
    Breast Cancer Res Treat; 2003 Dec; 82(3):215-22. PubMed ID: 14703069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
    J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.